Estimates of mortality associated with seasonal influenza for the European Union from the GLaMOR project

The European Centres for Disease Prevention and Control (ECDC) estimates that seasonal influenzacauses 4–50 million symptomatic infections in the EU/EEA each year and 15,000–70,000 European citizens die of causes associated with influenza. We used modelling methods to estimate influenza-associated m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2022-02, Vol.40 (9), p.1361-1369
Hauptverfasser: Paget, John, Danielle Iuliano, A., Taylor, Robert J., Simonsen, Lone, Viboud, Cecile, Spreeuwenberg, Peter
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The European Centres for Disease Prevention and Control (ECDC) estimates that seasonal influenzacauses 4–50 million symptomatic infections in the EU/EEA each year and 15,000–70,000 European citizens die of causes associated with influenza. We used modelling methods to estimate influenza-associated mortality for the European Union by age group and country. We compiled influenza-associated respiratory mortality estimates for 31 countries around the world (11 countries in the EU) during 2002–2011 (excluding the 2009 pandemic). From these we extrapolated the influenza mortality burden for all 193 countries of the world, including the 28 countries of the EU, using a multiple imputation approach. To study the effect of vaccination programs, we obtained data from the EU-funded VENICE project regarding the percentage of persons over 65 who were vaccinated in each country; the data ranged from 2% to 82% between the 21 countries which provided estimates for the 2006/07 reference season. We estimated that an average of 27,600 (range 16,200-39,000) respiratory deaths were associated with seasonal influenza in the 28 EU countries per winter; 88% were among people 65 years and older, and the rates of mortality in this age group were roughly 35 times higher compared with those 
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2021.11.080